Johnson & Johnson’s US$1bn Investment for Vision & Eye Care

“By further strengthening our Vision operations in Jacksonville with next-generation manufacturing, packaging and distribution capabilities, we are enhancing the resilience of our US supply chain while helping more people see better and live better.

“This commitment reflects the confidence we have in our people, our technology and our more than 40-year legacy of advancing eye health globally.”

By investing in next-generation technologies, Johnson & Johnson is positioning itself to better serve the evolving needs of eye care consumers and healthcare professionals.

Strengthening healthcare supply chains

The Jacksonville expansion reflects Johnson & Johnson’s broader strategy to reinforce domestic healthcare manufacturing and distribution infrastructure.

Company leadership emphasised that advanced manufacturing in the US plays a critical role in delivering innovative, high-quality healthcare solutions for patients.

The investment forms part of Johnson & Johnson’s previously announced US$55bn commitment to US manufacturing, research and development and technology through early 2029.

Construction of the new facility is already underway, with full operations expected to begin in 2028.

“Johnson & Johnson’s commitment is a strong vote of confidence in Jacksonville, our workforce and our future,” says Mayor Donna Deegan.

Source link

Johnson & Johnson Announces Another $1B US Manufacturing Plant

Johnson & Johnson announced plans to invest more than $1 billion in another new, US-based manufacturing site, this time in Florida. 

The global pharmaceutical manufacturer’s aim in building the new, Jacksonville facility is to strengthen its Vision operations by scaling US-based manufacturing, packaging, and distribution capabilities, according to a company news release. 

The investment also includes advanced manufacturing and packaging technologies to expand capacity and meet growing demand for Johnson & Johnson’s Acuvue brand contact lenses, used by more than 40 million patients worldwide, according to the company. The global pharmaceutical company manufactures more than 1.7 billion Acuvue contact lenses annually for US patients.

“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world,” Joaquin Duato, chairman and chief executive officer of Johnson & Johnson, said in the news release. 

Related:Lilly to Acquire 3 Vaccine Manufacturers

Duato added in the news release that the investment will bolster the resilience of Johnson & Johnson’s US supply chain. 

The global pharmaceutical manufacturer stated in the news release that it initially established a presence in Jacksonville in 1981 and has more than 1.5 million square feet of manufacturing, research, distribution, and operations facilities in the city today. 

The new facility is part of the pharmaceutical manufacturer’s previously announced $55 billion US investment in manufacturing, research and development, and technology through early 2029. Construction of the new facility is underway. J&J expects it to be fully operational in 2028.

The investment builds on J&J’s $6 billion annual economic impact in Florida, and supports the continued growth of its Jacksonville operations, strengthening opportunities for the 3,500 employees based in the area while reinforcing the regional economy.

In February, the global drug maker announced another investment of more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, PA. Additionally, in North Carolina, Johnson & Johnson is building a $2 billion drug product manufacturing facility.

The considerable investment is part of a larger push by pharmaceutical manufacturers to onshore or reshore their facilities, in part to avoid tariffs. Companies that are investing in building and expanding US-based facilities and research centers as part of three-year agreements include: 

Related:How CDMOs Turn “Undruggable” Into “Developable”

The multinational drug maker also announced plans to invest in a new Pennsylvania-based manufacturing facility — to the tune of more than $3.5 billion — in February.

In September, it started construction of its new active pharmaceutical ingredient (API) manufacturing plant in North Chicago, and announced a $1.95 billion investment to expand API production in the US in August 2025.

Related:Sun Pharma to Acquire US Drug Maker

Source link

Johnson & Johnson Raises U.S. Vision Manufacturing Capacity With More Than $1 Billion Jacksonville Investment

Johnson & Johnson announced an investment of more than $1 billion to expand its Vision operations in Jacksonville, Florida, strengthening the company’s U.S.-based manufacturing, packaging, and distribution capabilities for its ACUVUE-brand contact lenses.

The investment includes the construction of a new distribution facility and the addition of advanced manufacturing and packaging technologies designed to increase capacity and meet growing demand for the company’s contact lens products. The expansion is intended to support eye health solutions used by more than 40 million patients in the United States and globally.

The project is part of Johnson & Johnson’s previously announced $55 billion commitment to U.S. manufacturing, research and development, and technology through early 2029. Construction of the new Jacksonville facility is already underway, and the site is expected to become fully operational in 2028.

Johnson & Johnson said the expansion builds on its approximately $6 billion annual economic impact in Florida and supports continued growth for its Jacksonville operations. The company currently employs about 3,500 people in the area.

Jacksonville has served as a key center for the company’s vision business for more than 40 years. Since establishing operations there in 1981, Johnson & Johnson has expanded to more than 1.5 million square feet of manufacturing, research, distribution, and operations facilities. The company currently manufactures more than 1.7 billion ACUVUE contact lenses annually for U.S. patients.

Local, state, and federal officials said the investment will strengthen healthcare manufacturing capabilities, create jobs, and reinforce Northeast Florida’s role in the life sciences and advanced manufacturing sectors.

KEY QUOTES:

“This investment reinforces our long-standing conviction that advanced manufacturing in the United States is essential to delivering innovative, high quality healthcare solutions to patients at home and around the world. By further strengthening our Vision operations in Jacksonville with next-generation manufacturing, packaging and distribution capabilities, we are enhancing the resilience of our U.S. supply chain while helping more people see better and live better. This commitment reflects the confidence we have in our people, our technology, and our more than 40-year legacy of advancing eye health globally.”

Joaquin Duato, Chairman And Chief Executive Officer, Johnson & Johnson

“Johnson & Johnson’s commitment is a strong vote of confidence in Jacksonville, our workforce, and our future. Jacksonville continues to lead in advanced manufacturing and life sciences innovation. This expansion strengthens our high-tech footprint while creating quality jobs and long-term opportunities for our community.”

Donna Deegan, Mayor Of Jacksonville

“Florida continues to play a leading role in strengthening America’s healthcare supply chain to better serve patients. The billion-dollar investment in Jacksonville will help expand the domestic capacity and strengthen America’s healthcare infrastructure. That means more jobs in Florida, a stronger national economy, less reliance on foreign healthcare products, and better results for our nation’s long-term health and competitiveness.”

Rick Scott, U.S. Senator

“I am thrilled to see this major $1 billion investment in our state, funding new state of the art facilities and supporting jobs in the Jacksonville area. This is more than simple investment – this represents a down payment on the future of Jacksonville and the state of Florida. Companies are moving to Florida in droves, and massive investment such as this highlights Florida as the nation’s top state to grow your family and your business.”

Ashley Moody, U.S. Senator

“Johnson & Johnson’s continued investment in Jacksonville reflects the region’s strength in advanced manufacturing and critical healthcare production. It supports a skilled workforce, strengthens domestic capacity, and reinforces Northeast Florida’s role in keeping America economically competitive.”

John Rutherford, U.S. Representative

“Johnson & Johnson’s $1 billion investment in Jacksonville will strengthen the supply chain for critical vision products while creating high-quality jobs and generating significant economic benefits for Northeast Florida. The project reinforces Jacksonville’s status as a premier destination for healthcare manufacturing and innovation, helping ensure the region remains at the forefront of supporting patients and advancing medical technology.”

Aaron Bean, U.S. Representative

Source link

Johnson & Johnson Reaches Agreement with U.S. Government to Improve Access to Medicines and Lower Costs for Millions of Americans; Delivers on U.S. Manufacturing and Innovation Investments

Voluntary agreement will allow millions of Americans to purchase medicines at significantly discounted rates

Agreement provides Johnson & Johnson pharmaceutical products an exemption from U.S. tariffs

Company announces two new additional manufacturing facilities to be built in North Carolina and Pennsylvania; continues to deliver on $55 billion U.S. investment

NEW BRUNSWICK, N.J.–(BUSINESS WIRE)–Johnson & Johnson (NYSE: JNJ) (the “Company”), healthcare’s leading, most comprehensive innovation powerhouse, today announced a voluntary agreement with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The joint agreement meets the requests laid out by President Trump to the industry and provides the Company’s pharmaceutical products an exemption from tariffs1.

“Today’s agreement shows that when the public and private sectors work together towards shared goals, we can deliver real results for patients and the U.S. economy,” said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. “I’m proud that Johnson & Johnson is answering President Trump’s call to lower drug prices for everyday Americans while maintaining our role in improving and saving lives and ensuring that the United States continues to lead the world in healthcare innovation.”

Improving Access and Lowering Costs for U.S. Patients

Johnson & Johnson is working with the Trump Administration to improve access to medicines and lower costs for millions of American patients. The Company is:

• Participating in TrumpRx.gov, a direct to patient platform, which will allow millions of American patients to purchase medicines from Johnson & Johnson at significantly discounted rates.
• Enabling American patients to access medicines at comparable prices to other developed countries.
• Providing Medicaid program access at comparable prices to other developed countries.
• Continuing to support the Administration’s efforts to ensure better recognition of the value of health care across developed markets globally.

Delivering On Our $55B U.S. Investment

Johnson & Johnson also continues to deliver on our previously announced $55 billion investment to support U.S. manufacturing, research and development, and technology investments by early 2029. In just the last 10 months, the Company has initiated billions of dollars in investment in U.S. manufacturing, which will support the Company’s goal of manufacturing the vast majority of its advanced medicines in the U.S. to meet the needs of U.S. patients.

Today, as part of the $55 billion investment, the Company is announcing two new U.S. manufacturing facilities, including a next generation cell therapy manufacturing site in Pennsylvania and a state-of-the-art drug product manufacturing facility in North Carolina.

Additionally, construction is progressing on our $2 billion state-of-the-art biologics manufacturing facility in Wilson, North Carolina, which the Company broke ground on last year. That project will create approximately 5,000 skilled manufacturing and construction jobs in the state. Johnson & Johnson is already ramping up the hiring of advanced manufacturing employees to work at the facility.

In September, the Company also secured a new 160,000+ square foot dedicated biopharmaceutical manufacturing site in Holly Springs, North Carolina. The $2 billion commitment over the next 10 years will create approximately 120 new jobs in North Carolina.

Johnson & Johnson expects to announce additional U.S. investments later this year.

About Johnson & Johnson:

At Johnson & Johnson, we believe health is everything. Our strength in healthcare innovation empowers us to build a world where complex diseases are prevented, treated, and cured, where treatments are smarter and less invasive, and solutions are personal. Through our expertise in Innovative Medicine and MedTech, we are uniquely positioned to innovate across the full spectrum of healthcare solutions today to deliver the breakthroughs of tomorrow and profoundly impact health for humanity. Learn more at www.jnj.com.

Cautions Concerning Forward-Looking Statements

This press release contains “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: challenges and uncertainties inherent in product research and development, including the uncertainty of clinical success and of obtaining regulatory approvals; uncertainty of commercial success; manufacturing difficulties and delays; competition, including technological advances, new products and patents attained by competitors; challenges to patents; product efficacy or safety concerns resulting in product recalls or regulatory actions; changes in behavior and spending patterns of purchasers of health care products and services; changes to applicable laws and regulations, including global health care reforms; and trends toward health care cost containment. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson’s most recent Annual Report on Form 10-K, including in the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s subsequent Quarterly Reports on Form 10-Q and other filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

1 Specific terms of the agreement remain confidential.

Contacts

Media contact:
media-relations@its.jnj.com

Investor contact:

investor-relations@its.jnj.com

Source link